Navigation Links
Multiple lipomas within jejunal duplication cyst

Lipoma of the small intestine is a benign tumor of mesenchymal origin which is mostly found by chance during gastrointestinal investigation. Invaginations account for 2/3 of small bowel occlusion caused by up to 80% of tumors and the lipoma is the most frequent benign tumor that causes invagination in its submucous polypoid and it is in more or less scissile form. However, multiple lipomas within the intestinal duplication canal as a predominant cause of partial intestinal obstruction is an exceptional clinical scenario.

A research article to be published on May 7, 2010 in the World Journal of Gastroenterology addresses this question. The research team from Department of Gastroenterology, Renmin Hospital of Wuhan University, reported a case of a 68-year-old man with a 10-d history of abdominal bloating after meals caused by intussusception due to a small intestine lipomatous lesion located in the jejunal duplication cyst.

Multiple lipomas within jejunal duplication cysts are rare and difficult to diagnose before surgery. This case highlights small intestinal lipoma, though uncommon, should be included in the differential diagnosis of intestinal obstruction and appropriate examination methods should be chosen. Such a case found by double-balloon endoscopy is an example to remind doctors to be vigilant in diagnosing patients with intestinal obstruction and in choosing appropriate examinations.


Contact: Ye-Ru Wang
World Journal of Gastroenterology

Page: 1

Related medicine news :

1. Catching multiple sclerosis before it strikes
2. Statins May Slow Progression of Multiple Sclerosis, New Study Finds
3. Statins may slow progression of multiple sclerosis, new study finds
4. Free CME/CE Lecture and Workshop on Multiple Sclerosis: Boise, ID
5. Clinical benefit of multiple sclerosis drug discovered at Rush University Medical Center
6. Damaka Delivers Advanced Sweeping™ Capability of Live Sessions Across Multiple Devices Over WiFi, 3G and 4G Networks
7. Discovery May Lead to Better Multiple Sclerosis Treatments
8. Kineta Awarded NIH Grant to Complete Preclinical Studies on Type 1 Diabetes / Multiple Sclerosis Drug Candidate
9. Sunwin International & WILD Flavors Receive GRAS Letters of No Objection from FDA Validating Safety of Multiple Sunwin Stevia Extracts
10. 'Miracles For MSA' Proclaims March as Multiple System Atrophy Awareness Month
11. MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... for the care management and population health arenas, is pleased to announce that ... cost containment services, has successfully implemented the ACUITY Complete Care™ Management to back ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash Moradzadeh ... Man for 2015. , Angeleno Magazine is a division of Modern Luxury, ... 1994, Modern Luxury includes more than 50 magazine titles across 15 major markets. ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announced today that it has officially launched a sleek, mobile-ready and user-centric redesigned ... his company’s new website clearly outlines the benefits that its SEO services provide ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015 Breg, Inc ., a premier ... that it has been awarded three contracts by Novation, ... Novation will have access to improved pricing for Breg,s ... soft goods dedicated to advancing orthopedic care.  ... U.S. population, rising prevalence of chronic conditions and the ...
(Date:12/1/2015)... Russia has always been a country of choice ... in Europe in 2015 were tested in phase ... has always been a country of choice for global multi-center ... Europe in 2015 were tested in phase II-III clinical ... has always been a country of choice for global multi-center phase III ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology: